Christos E. Kyriakopoulos

Nov 1, 2024 | jitc.bmj.com | Christos E. Kyriakopoulos |Jens Eickhoff |Laura Johnson |Tommaso P Tonelli

AbstractBackground We have previously evaluated a DNA vaccine encoding the ligand-binding domain of the androgen receptor (AR, pTVG-AR) in patients with metastatic prostate cancer. In murine studies we have demonstrated that the anti-tumor efficacy of androgen deprivation (ADT) can be improved using pTVG-AR vaccination, and that anti-tumor efficacy of vaccination can be improved with concurrent PD-1 blockade.

Oct 9, 2024 | urotoday.com | Christos E. Kyriakopoulos

Read the Full Video TranscriptZachary Klaassen: Hi, my name is Zach Klaassen. I'm a urological oncologist at the Georgia Cancer Center in Augusta, Georgia. I'm delighted to be joined on UroToday for an ESMO discussion with Dr. Christos Kyriakopoulos from the University of Wisconsin. Christos, thanks very much for joining us today. Christos Kyriakopoulos: Hi, Dr. Klaassen, and thank you so much for the invitation to discuss the results of this very exciting trial. Zachary Klaassen: Absolutely.

Jun 25, 2024 | onclive.com | Christos E. Kyriakopoulos

Christos Kyriakopoulos, MD, of the University of Wisconsin Carbone Cancer Center, presents findings from the CHAARTED2 trial (NCT03419234), which evaluated the efficacy of adding cabazitaxel (Jevtana) to abiraterone (Zytiga)/prednisone (Rayos) in patients with metastatic castration-resistant prostate cancer who had previously been treated with androgen deprivation therapy (ADT) and docetaxel for hormone-sensitive prostate cancer.

Jun 11, 2024 | urotoday.com | Christos E. Kyriakopoulos

Read the Full Video TranscriptAlicia Morgans: Hi, I'm so excited to be here today with Dr. Christos Kyriakopoulos, who is joining me from the University of Wisconsin-Madison, as well as ASCO 2024, where he presented the CHAARTED 2 data, which is very exciting. Thank you so much for being here with me today. Christos Kyriakopoulos: Thank you very much, Dr. Morgans, for the invitation. I'm really excited to be here. Alicia Morgans: Well, I am always excited to talk to you, Christos.

Jan 31, 2024 | onclive.com | Christos E. Kyriakopoulos

Christos Kyriakopoulos, MD, medical oncologist, associate professor, Department of Medicine, Division of Hematology, Medical Oncology and Palliative Care, the University of Wisconsin School of Medicine and Public Health, discusses initial safety, pharmacokinetic, and efficacy findings with the addition of masofaniten (EPI-7386) to enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).